Hsbc Holdings PLC Invests $7.64 Million in Palvella Therapeutics, Inc. $PVLA

Key Points

• HSBC Holdings acquired 50,001 Palvella Therapeutics shares worth approximately $7.64 million, representing a 0.35% stake. Other major institutions, including BlackRock, Vanguard and State Street, also increased or initiated positions, while institutional investors collectively own 40.11% of the company.
• Analysts maintain a broadly positive outlook, with a consensus “Buy” rating and an average price target of $209.14, despite one sell rating.
• PVLA opened at $149.97, near its 52-week high, but reported a quarterly loss of $1.52 per share—worse than the expected $1.17 loss. Separately, COO Kathleen Goin sold $654,807 worth of shares under a pre-arranged trading plan.

Hsbc Holdings PLC acquired a new position in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 50,001 shares of the company's stock, valued at approximately $7,641,000. Hsbc Holdings PLC owned 0.35% of Palvella Therapeutics as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in Palvella Therapeutics in the second quarter valued at approximately $140,343,000. Summit Partners Public Asset Management LLC boosted its position in shares of Palvella Therapeutics by 1,016.0% during the fourth quarter. Summit Partners Public Asset Management LLC now owns 389,420 shares of the company's stock worth $40,761,000 after buying an additional 354,525 shares during the period. Vanguard Group Inc. boosted its position in shares of Palvella Therapeutics by 202.0% during the third quarter. Vanguard Group Inc. now owns 494,656 shares of the company's stock worth $31,010,000 after buying an additional 330,847 shares during the period. State Street Corp grew its stake in shares of Palvella Therapeutics by 206.3% in the fourth quarter. State Street Corp now owns 420,462 shares of the company's stock valued at $44,010,000 after buying an additional 283,211 shares in the last quarter. Finally, Jennison Associates LLC grew its stake in shares of Palvella Therapeutics by 262.4% in the fourth quarter. Jennison Associates LLC now owns 387,483 shares of the company's stock valued at $40,558,000 after buying an additional 280,573 shares in the last quarter. Institutional investors and hedge funds own 40.11% of the company's stock.

Wall Street Analysts Forecast Growth

PVLA has been the topic of several analyst reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Palvella Therapeutics in a research note on Monday, June 29th. Stephens reissued an "overweight" rating and set a $220.00 target price on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Canaccord Genuity Group set a $232.00 price target on Palvella Therapeutics in a report on Wednesday, August 5th. HC Wainwright reaffirmed a "buy" rating and issued a $270.00 price target on shares of Palvella Therapeutics in a research report on Wednesday, July 22nd. Finally, Truist Financial set a $207.00 price objective on Palvella Therapeutics in a research note on Wednesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $209.14.

Palvella Therapeutics Stock Down 0.2%

Shares of PVLA opened at $149.97 on Friday. The stock has a 50 day moving average price of $146.01 and a 200 day moving average price of $126.90. The company has a market capitalization of $2.16 billion, a price-to-earnings ratio of -31.05 and a beta of -0.17. Palvella Therapeutics, Inc. has a 52-week low of $49.81 and a 52-week high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.35). On average, equities analysts anticipate that Palvella Therapeutics, Inc. will post -6.36 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Kathleen Goin sold 4,302 shares of the business's stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $152.21, for a total value of $654,807.42. Following the completion of the sale, the chief operating officer directly owned 2,154 shares of the company's stock, valued at $327,860.34. The trade was a 66.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.20% of the stock is owned by corporate insiders.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc NASDAQ: PVLA is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella's pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.

Want to see what other hedge funds are holding PVLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source